Education
About Us
Working with TipRanks
Follow Us
Akari Therapeutics PLC (ADR) (AKTX)
:AKTX
Total Valuation
Akari Therapeutics has a market cap or net worth of $11.06M. The enterprise value is $35.60M.
Market Cap$11.06M
Enterprise Value$35.60M
Share Statistics
Akari Therapeutics has 35,739,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding35,739,730
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Akari Therapeutics’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -63.82%.
Return on Equity (ROE)-0.89
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-63.82%
Return on Capital Employed (ROCE)-0.71
Revenue Per Employee0.00
Profits Per Employee-2.47M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Akari Therapeutics is ―. Akari Therapeutics’s PEG ratio is >-0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.00001
Income Statement
In the last 12 months, Akari Therapeutics had revenue of 0.00 and earned -19.79M in profits. Earnings per share was -1.66K.
Revenue0.00
Gross Profit0.00
Operating Income-21.64M
Pretax Income-19.79M
Net Income-19.79M
EBITDA-19.53M
Earnings Per Share (EPS)-1.66K
Cash Flow
In the last 12 months, operating cash flow was -9.63M and capital expenditures 0.00, giving a free cash flow of -9.63M billion.
Operating Cash Flow-9.63M
Free Cash Flow-9.63M
Free Cash Flow per Share-0.27
Dividends & Yields
Akari Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-66.00%
50-Day Moving Average0.69
200-Day Moving Average1.01
Relative Strength Index (RSI)27.69
Average Volume (3m)933.62K
Important Dates
Akari Therapeutics upcoming earnings date is Apr 7, 2026, TBA (Confirmed).
Last Earnings DateSep 25, 2025
Next Earnings DateApr 7, 2026
Ex-Dividend Date―
Financial Position
Akari Therapeutics as a current ratio of 0.15, with Debt / Equity ratio of 9.33%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap223.72
Net Debt to EBITDA-0.03
Interest Coverage Ratio88.70
Taxes
In the past 12 months, Akari Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Akari Therapeutics EV to EBITDA ratio is -0.03, with an EV/FCF ratio of -0.05.
EV to Sales0.00
EV to EBITDA-0.03
EV to Free Cash Flow-0.05
EV to Operating Cash Flow-0.05
Balance Sheet
Akari Therapeutics has $2.48M in cash and marketable securities with $2.12M in debt, giving a net cash position of $367.00K billion.
Cash & Marketable Securities$2.48M
Total Debt$2.12M
Net Cash$367.00K
Net Cash Per Share$0.01
Tangible Book Value Per Share-$2.12K
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Akari Therapeutics is $4.53, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.53
Price Target Upside906.67% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―